Search within the Lindenbaum website

home / news & insights /

Amsterdam, 24 January 2023

Damiën Berkhout speaks about collective actions

By Damiën Berkhout

On 24 January 2023, Damiën Berkhout provided a lecture on Dutch collective actions under the WAMCA at Utrecht University. He did so together with Ms Branda Katan, a partner at Stibbe. The lecture focussed on key steps in Dutch class actions, with Mr Berkhout providing insights from the plaintiffs perspective, and Ms Katan from a defence perspective.

Lindenbaum’s attorneys have been involved in some of the largest WAMCA procedures up to date, such as Take Back Your Privacy’s claims against TikTok on behalf of all Dutch children, and the claim by the Consumer Competition Claims Foundation against Apple. Mr. Berkhout has been lead counsel in WAMCA’s and other class actions, successfully representing both plaintiffs and defendants.

Do you have questions about the WAMCA, or do you want to receive our insights? Be sure to sign up to our newsletter.

Damiën Berkhout

Partner, dispute resolution expert

Contact

More publications

Lindenbaum moves into its new offices in Amsterdam: Concertgebouwplein 13

25 September 2024 - Insights

Lindenbaum is moving to its new Amsterdam offices at Concertgebouwplein 13. We look forward to meeting you there.

Read more

Lindenbaum represents Beequip’s management board

5 September 2024 - Insights

Lindenbaum's managing partner Damiën Berkhout provided legal and governance advice to the management board of Beequip in the context of the transaction between NIBC and Apollo.

Read more

Collective action on excessive pricing of pharmaceuticals moves on to merits phase

5 September 2024 - News

The Amsterdam District Court ruled that the representative organization Stichting Farma Ter Verantwoording is admissible in its collective action against pharmaceutical giant AbbVie. The case now moves on to the merits phase, in which the court will assess whether Abbvie abused its dominant position and violated human rights by charging excessive prices for its Humira medicine.

Read more